Orthofix’s trauma sales have always been weighted heavily toward Europe, where its offering and presence have become very mature and, perhaps, a bit stagnant.
By late 2023, the company faced questions from Wall Street about why it was staying in a segment that was generating little growth and profit.
“Orthopedics is the DNA of this organization,” said Orthofix CEO Massimo Calafiore. “I think what we see in front of us is an enormous opportunity in United States, where we have a very small market share. There is a lot of focused investment that right now we are making in the specific market, not just around the marketing and sales, but also innovation. With the United States market that grows much faster, you will automatically see a much higher profitability.”
Our chart of the month looks at the historical trend of Orthofix’s trauma sales in the U.S. and internationally.
Since 2017, the company’s U.S. and OUS trauma CAGRs are 5% and 3%, respectively. However, sales in the United States have accelerated nicely since 2021, with a CAGR of 12%. The last three years have been especially fruitful, with an average growth rate in the mid-teens.
At the end of 2025, Orthofix rebranded its orthopedics business as Limb Reconstruction, with a strategic focus on high-value areas like limb preservation, limb lengthening, deformity correction, and complex fracture care.
Orthofix Trauma Sales 2017 to 2025
Orthofix's trauma sales have always been weighted heavily toward Europe, where its offering and presence have become very mature and, perhaps, a bit stagnant.
By late 2023, the company faced questions from Wall Street about why it was staying in a segment that was generating little growth and...
Orthofix Trauma Sales 2017 to 2025
Orthofix’s trauma sales have always been weighted heavily toward Europe, where its offering and presence have become very mature and, perhaps, a bit stagnant.
By late 2023, the company faced questions from Wall Street about why it was staying in a segment that was generating little growth and profit.
“Orthopedics is the DNA of this organization,” said Orthofix CEO Massimo Calafiore. “I think what we see in front of us is an enormous opportunity in United States, where we have a very small market share. There is a lot of focused investment that right now we are making in the specific market, not just around the marketing and sales, but also innovation. With the United States market that grows much faster, you will automatically see a much higher profitability.”
Our chart of the month looks at the historical trend of Orthofix’s trauma sales in the U.S. and internationally.
Since 2017, the company’s U.S. and OUS trauma CAGRs are 5% and 3%, respectively. However, sales in the United States have accelerated nicely since 2021, with a CAGR of 12%. The last three years have been especially fruitful, with an average growth rate in the mid-teens.
At the end of 2025, Orthofix rebranded its orthopedics business as Limb Reconstruction, with a strategic focus on high-value areas like limb preservation, limb lengthening, deformity correction, and complex fracture care.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
